EcoDrugPlus

Glucagon Receptor

Ensembl ID : ENSNBRG00000017113
Gene Symbol: GCGR
1 Cross references
164 Possible Orthologues:

Glucagon-Like Peptide 2 Receptor-Like

Ensembl ID : ENSNBRG00000012607
Gene Symbol: LOC102785509
3 Cross references
204 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSNBRG00000002569
Gene Symbol: LOC102780526
3 Cross references
193 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSNBRG00000012902
Gene Symbol: LOC102792209
3 Cross references
205 Possible Orthologues:

Glucokinase-Like

Ensembl ID : ENSNBRG00000020875
Gene Symbol: LOC102789388
3 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSNBRG00000003782
Gene Symbol: GBA1
3 Cross references
251 Possible Orthologues:

Glutamate Carboxypeptidase 2-Like

Ensembl ID : ENSNBRG00000015456
Gene Symbol: LOC102780247
3 Cross references
339 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSNBRG00000007840
Gene Symbol: GRIA2
3 Cross references
242 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSNBRG00000024316
Gene Symbol: GRIN1
3 Cross references
176 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSNBRG00000007262
Gene Symbol: GRIN2A
3 Cross references
228 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSNBRG00000001736
Gene Symbol: GRIN2B
3 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSNBRG00000007292
Gene Symbol: GRIN2C
3 Cross references
249 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).